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Expression of ABC family transporter proteins that promote drug efflux from cancer cells
is a widely observed mechanism of multi-drug resistance of cancer cells. Cell adaptation in
long-term culture of HL60 leukemic cells in the presence of chemotherapy leads to induc-
tion and maintenance of the ABC transporters expression, preventing further accumulation
of drugs. However, we found that decreased accumulation of drugs and fluorescent dyes
also contributed by a reduced uptake by the resistant cells. Confocal time-lapse microscopy
and flow cytometry revealed that fluid-phase endocytosis was diminished in drug-resistant
cells compared to drug-sensitive cells. Drug uptake was increased by insulin co-treatment
when cells were grown in methylcellulose and monitored under the microscope, but not
when cultured in suspension. We propose that multi-drug resistance is not only solely
achieved by enhanced efflux capacity but also by supressed intake of the drug, offering an
alternative target to overcome drug resistance or potentiate chemotherapy.
Keywords: endocytosis-related multi-drug resistance, ABC transporters dependent drug resistance, cellular
responses to anticancer drugs, novel mechanism of multi-drug resistance, acute myeloid leukemia model
INTRODUCTION
Endocytosis is used by all cells to take up solutes from their
surroundings (1–6). The process of endocytosis can be energy-
dependent or independent and contributes to the cells’ inter-
action with their environment. Fluid-phase endocytosis (or
macropinocytosis) can be defined as the uptake of extra-cellular
medium into cells by vesicular endocytosis (3, 7–12) (Figure 1A)
and is the entry route for non-selective endocytosis of macromole-
cules (1, 5, 9, 13–15). In fluid-phase endocytosis, the uptake of the
extra-cellular fluid is proportional to the concentration of mol-
ecules outside the cell (3, 16–19). In contrast, internalization of
hormones and nutrients, as well as toxins and pathogens, typically
occurs via receptor-mediated endocytosis. Some signaling path-
ways are controlled by differential endocytosis, which mediates
recycling and ensues degradation of cell surface receptors (3, 18,
20, 21). Moreover, the regulation of endocytosis can also control
the extent of drug delivery to a cell and disruptions of this process
may have consequences in disease development (22–26).
Because pharmacological drugs are developed through a
lengthy optimization processes that prioritizes cell permeability,
it is commonly assumed that when they are finally approved, they
can cross the cell membrane easily (2, 3, 22, 24, 26–28). There-
fore, the lack of accumulation of drug molecules in drug-resistant
cancer cells has been explained by their capacity to eject drugs (3,
7, 10, 20, 29–31). In this perspective, a drug-resistant cell whose
resistance is conferred by the overexpression of a member of the
ABC transporter family, such as MDR1 (9, 13–15, 23), accumulates
a lesser amount of drug inside the cell because the transporters effi-
ciently carry the drug out of the cell (23). This phenomenon has
been established and validated many times (8, 11, 12, 16, 17, 19). A
straightforward approach of blocking ABC transporters activity to
counter drug resistance in cancer had focused on using competitive
inhibitors that bind to the transporter with at least the same affinity
as the drug, thereby preventing cellular detoxification and leading
to intracellular drug accumulation (1–3, 27, 28). What this model
neglects is how the drug enters the cell in the first place: the net
intracellular concentration of a drug is a balance between its accu-
mulation due to the uptake and its clearance by the transporter-
facilitated efflux (Figure 1B). The current model assumes that
drug uptake is constant because the influx of the drug into the cell
is taken for granted. However, drug resistance may also be a con-
sequence of reduced endocytosis/influx of cytotoxic drugs (3, 20).
Here, we ask whether modulation of intake can also con-
tribute to the acquisition of drug resistance phenotype following
chemotherapy treatment. We recently showed that inhibition of
drug accumulation as a resistance mechanism in HL60 cells is not
simply the result of a Darwinian selection for cells with muta-
tions that endow them with capacity of high rate of drug ejection,
but instead, reflects an active, drug induced cellular response con-
ferred by rapid up-regulation of expression of MDR1 (22, 23).
Interestingly, we found that propidium iodide (PI) and doxoru-
bicin uptake differed in HL60-treatment-naïve (HL60-parental)
versus HL60-vincristine resistant cells. By studying HL60-parental
cells and HL60 cells resistant to 10 nM of vincristine (HL60-10R)
and to 100 nM of vincristine (HL60-100R), we were able to show
that a reduction in fluid-phase endocytosis appeared at the late
stage of cellular adaptation to the drug and was necessary for a sta-
ble MDR phenotype. While verapamil, a well-known inhibitor of
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FIGURE 1 | Fluid-phase endocytosis in HL60-parentals and HL60-100R.
(A) Schematic representation of fluid-phase endocytosis. Pinocytotic vesicles
fuse with lysosomes that hydrolyze the pinocytosed material. (B) Unlike
receptor-mediated endocytosis, pinocytosis is non-specific to the substances
that it transports. The cellular net balance between endocytosis (endo) and
exocytosis (exo) regulates the accumulation of drug inside the cells. (C) PI
accumulation in HL60-parentals and HL60-100R. Dye accumulation was
measured using flow cytometry. PI was added just before flow cytometry
analysis of HL60-parental cells and HL60-100R. The cells, initially at room
temperature, where kept on ice until analysis. The differential PI accumulation
is only seen on the left peak (cells that take up PI via endocytosis), not on the
small far right peak (dead cells). The second peak is barely noticeable for
HL60-parentals but zooming reveals the overlap (inset). (D) HL60-parentals
and HL60-100R were incubated for 15 min at 15°C with PI. As control,
HL60-parentals and HL60-100R cells were kept in the incubator and PI was
added just as in (C). Results in (D) are representative of n=3 biological
replicates. The results in (C) were consistently observed every time an
analysis was performed.
MDR1, was not able to re-establish the drug accumulation balance
observed in non-resistant cells, two endocytosis facilitating agents,
PMA and insulin, promoted drug accumulation in the resistant
cells. Taken together, our results suggest that a model in which
expression of ABC transporters prevent drug accumulation in the
resistant cell by improving efflux must be extended by considering
the other side of the equation, the suppression of drug influx by
active reduction of endocytosis.
RESULTS
HL60-100R CELLS DO NOT ACCUMULATE PI TO THE SAME EXTENT AS
HL60-PARENTAL CELLS
Propidium iodide flow cytometric assay is routinely used to evalu-
ate population viability by discriminating live (dye negative) from
dead (dye positive) cells in many different types of cells (8, 9, 11,
12, 24, 26, 33). It is commonly assumed that viable cells are not
permeable to PI and that PI labeled cells represent dead cells. PI
binds to DNA by intercalating between the bases with a stoichiom-
etry of one dye per 4–5 bp of DNA (1, 3, 5, 6) and once the dye is
bound to nucleic acids, its fluorescence is enhanced 20- to 30-fold
(13, 18, 23, 34). However, the use of this dye as a live/dead discrim-
inant must consider that PI actually can enter live cells through
fluid-phase endocytosis and has in fact been used as a marker for
this endocytic route (8, 9, 12, 17, 19, 24, 26, 35, 36).
After a short (∼5 min) incubation time, HL60-parental cells
were slightly but consistently more permeable (hence brighter)
to the dye than their resistant counterparts as evidence by flow
cytometry of PI treated cells (Figure 1C). The difference in the PI-
uptake profile between HL60-100R and HL60-parentals was con-
sistently observed. Without gating out the dead cells (Figure 1C),
one can observe that dead cells are about three-logs brighter than
live cells. This second peak on the far right of the fluorescence
intensity axis of the flow cytometry histograms was consistent
for all cell lines. Thus, even if a 5 min incubation at room tem-
perature is sufficient to load the cells, PI can still be used for
live/dead discrimination as the fluorescence intensity given by
dead cells is by orders of magnitude higher than the baseline sig-
nal on the left of the fluorescence intensity axis that is due to
endocytosis.
But why is the baseline of PI fluorescence in viable cells higher
in HL60-parental cells than in HL60-100R cells? There are two pos-
sible explanations. First, PI may be a substrate for MDR1; in that
situation, the resistant HL60-100R cells will have lower signal for
PI because these cells pump the dye out more efficiently. Second,
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it might be that conversely, the HL60-100R cells have lower basal
endocytosis for PI than the HL60-parental cells. This would also
explain why we observe the differences in such a short period of
time.
The most effective non-invasive method to inhibit fluid-phase
endocytosis is incubation at low temperatures (bellow 20°C) (7, 8,
10–12). To investigate if the observed difference between PI sig-
nal could be due to reduced endocytosis in the resistant cells we
incubated HL60-parental cells and HL60-100R cells at 15°C for 15′
with PI. As a control we used cells incubated at 37°C to which PI
was added only before the experiment (Figure 1D). When parental
cells were incubated at lower temperatures, their accumulation of
PI shifts to the range of HL60-100R. This suggests that it is more
likely that the reduced fluorescence is due to reduced uptake, rather
than a more efficient expulsion of PI.
PI ACCUMULATES IN LIVE HL60-PARENTAL AND HL60-100R CELLS
To show that PI indeed enters cells at different rates we followed
HL60-parental and HL60-100R cells over time using time-lapse
microscopy in cells seeded on a glass bottom dish and kept at
37°C, 5% CO2 (Figure 2). HL60-parental cells accumulate PI
much faster than HL60-100R (Figure 2A). PI did not interfere
with cellular viability, because the cells continue to proliferate
throughout the entire experiment. HL60-100R reached their maxi-
mum uptake in about 8 h, after which the intensity of intracellular
PI remained constant (Figure 2B). Quantitative analyses of the
images revealed that the accumulation of PI was significantly
different between HL60-parentals and HL60-100R (Figure 2C),
supporting the qualitative observations. Moreover, the observed
differences of drug accumulation are not due to differential growth
rates, as sensitive and resistant cells show an identical proliferation
profile (Figure 2D).
REDUCTION OF ENDOCYTIC ACTIVITY OCCURS AT THE LATTER STAGE
IN THE ESTABLISHMENT OF RESISTANCE
The different rates of PI accumulation in the naïve and the resis-
tant HL60 cells are not only visible in HL60-100R but also in the
HL60-10R cells that were adapted to lower doses of vincristine. To
determine when the phenotype of reduced endocytosis appears
during the adaptation process we increased the concentration of
FIGURE 2 | Propidium iodide endocytosis in HL60-parental and
HL60-100R cells. (A,B) Snapshot of the cell population after different
incubation times with PI. (C) Quantification of PI fluid-phase
endocytosis in HL60-parentals (blue) and HL60-100R (red). Each
data point represents the mean±SD of n=10 individual
cells. ****p-Value<0.0001 for time >8 h. (D) Growth curve for
HL60-parental, HL60-10R, and HL60-100R cells. p-value was calculated
by two-way ANOVA.
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the drug in a parallel culture of HL60-10R, from 10 to 100 nM
vincristine (HL60-10R- >100R cells) and compared it to a regu-
lar culture of HL60-10R where the vincristine challenge was not
increased. The kinetics of the adaptation of HL60-10R cells to this
higher amount of drug was monitored in a detailed time course
over the first 12 days of treatment. The data in Figure S1 in Sup-
plementary Material suggests that the magnitude of the shift of
PI accumulation depends on the degree of resistance (Figure S1A
in Supplementary Material): after a period of 12 days HL60-10R
cells accumulated less PI than HL60-parental cells and HL60-
100R cells (resistant to higher amounts of drug) accumulated
even less dye than HL60-10R cells. For the first 9 days, there were
no changes (Figures S1A–C in Supplementary Material): HL60-
10R and HL60-10R- >100R showed a complete overlap in PI
retention. However, at day 12, we observed that the cells in the
HL60-10R- >100R arm no longer accumulated as much PI as
HL60-10R (Figure S1D in Supplementary Material).
A semi-quantitative analysis of the ratio of the mean of each
peak relatively to the parental cells over time demonstrated the
trend of PI uptake to decrease in the HL60-10R- >100R culture
during its adaptation to a higher drug concentration (Figure S1E in
Supplementary Material): in 12 days, the relative mean of PI signal
changed by>30%, from a value close to HL60-parentals to a value
close to that of HL60-100R. The relative mean of the PI signal for
HL60-10R did not change in the same time interval. Although the
relative mean of the PI signal in HL60-100R slightly decreased,
the change was <10%. After ~20 days, HL60-10R- >100R cells
were resistant to 100 nM of vincristine (viability >95%) and the
PI intensity peak was identical to the one observed for HL60-100R.
FLUID-PHASE ENDOCYTOSIS IS BLOCKED IN HL60-100R
To determine if the reduced accumulation of PI was due to a
generic down-regulation of non-receptor-mediated fluid-phase
endocytosis, we also measured uptake of FITC-Dextran after
2 h of incubation at 37°C in HL60-parentals and HL60-100R
(Figures S3A,B in Supplementary Material). FITC-Dextran is a
well-established marker used to assess fluid-phase endocytosis
status (1, 9, 14, 15). Accumulation of the fluid-phase endocy-
tosis marker was significantly higher in HL60-parentals than in
HL60-100R (Figure 3A). After 2 h of incubation with 1 mg/mL
of FITC-Dextran at 37°C, we observed approximately three-
fold lower uptake of FITC-Dextran by HL60-100R cells when
compared to their sensitive counterparts (Figure 3B). Because
the auto-fluorescent background is higher in HL60-100R than in
HL60-parentals (Figure 3A; H2O control), we normalized each
independent replicate to its respective control, and calculated
the relative fold change. Although the SD was higher for HL60-
parentals, the average of the replicates indicated that the two cell
lines were significantly different regarding their rate of fluid-phase
endocytosis.
DOXORUBICIN UPTAKE IS DIMINISHED IN RESISTANT CELL LINES
Based on PI and FITC-Dextran as fluid-phase endocytosis mark-
ers, we have shown that endocytosis is lower in the resistant cell
lines. Yet, a reduction of endocytosis per se does not automati-
cally imply increased drug resistance. Thus, we next examined the
functional consequences of this reduced endocytosis by following
the uptake of doxorubicin, a well-established chemotherapeutic
drug known to be a substrate for MDR1. Because doxorubicin is
fluorescent, we can also use the drug fluorescence signal as the
direct reporter for intracellular drug accumulation. A saturating
(supra-maximal) concentration of doxorubicin was used to ensure
sufficient intake that could override the contribution of MDR1
activity.
Flow cytometry analysis of doxorubicin uptake up to 8 h of
incubation of cells with drug indicated a twofold higher uptake
in the HL60-parental cells compared to the HL60-100R cells dur-
ing the incubation period (Figures 3C,D). The amount of drug
accumulated in the HL60-100R cells reached a plateau about 4 h
after the treatment start. Since the control cell line continued
to accumulate, the drug was not degraded during the course of
the experiment. Taken together, these experiments indicate that
the down-regulation of drug fluid-phase endocytosis in HL60-
resistant cells had functional consequences. The reduced intracel-
lular accumulation of chemotherapeutical drugs, such as doxoru-
bicin, may suggest that perhaps the MDR phenotype is not only
achieved by increase efflux but is also accompanied by a reduction
in endocytosis. Confocal microscopy measurement corroborated
the results obtained with flow cytometry (Figures 3E,F). The net
uptake of doxorubicin in HL60-parental cells was much faster than
in the resistant cells and after 4 h the accumulation remain stable,
with approximately threefold difference in the intensity between
HL60-parental (blue) and HL60-100R cells (red). The observation
that MDR cells do not accumulate doxorubicin to the same extent
as parental cells is also corroborated by previous studies (3, 16).
PI IS NOT A SUBSTRATE OF MDR1
To further support the notion that suppression of PI accumulation
was due to down-regulation of endocytosis, rather than MDR1-
mediated efflux, we incubated HL60-parentals and HL60-100R
with verapamil and doxorubicin. Verapamil is a potent inhibitor
of ABC transporter activity (22, 27, 28). Incubation of all cell lines
with verapamil, prior to CaAM efflux assay, resulted in a signifi-
cant increase in dye accumulation (Figure 4A). If the differences
in the accumulation of doxorubicin between HL60-parental and
HL60-100R cells were solely due to drug efflux, verapamil should
abrogate these differences. We observed that in the presence of
verapamil the accumulation of doxorubicin was increased in the
HL60-100R cells (Figures 4B,C). Nevertheless, this response did
not suffice for the cells to reach the levels seen in the HL60-parental
cells and the difference in the net accumulation further increased
over time.
PMA CAN RESCUE THE PHENOTYPE
Since verapamil was not able to re-establish the net accumu-
lation by blocking the efflux, we next explored the increase in
uptake stimulated by phorbol-12-myristate-13-acetate (PMA),
a drug known to promote endocytosis (7, 10, 25, 37, 38).
HL60-parental and HL60-100R cells were co-treated with PMA
and PI. While baseline PI accumulation in HL60-100R was
significantly lower than in HL60-parental cells, in the presence
of PMA the accumulation was about the same level in both cell
lines (Figure 4D), suggesting that the uptake machinery in the
HL60-100R was still intact but suppressed. This result has practical
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FIGURE 3 | Parental and resistance cells have different uptake
capabilities. (A) Reduced accumulation of FITC-dextran in HL60-100R. Cells
were incubated with 1 mg/mL of FITC-dextran for 2 h at 37°C and the
accumulation was measured using flow cytometry. (B)The mean of the
accumulation peak measured by flow cytometry for n=4 independent
biological replicates was normalized to the respective H2O control. Scatter
plot shows the data together with mean and SD. The two data sets are
significantly different (*p-value=0.0286<0.05). p-value calculated by
unpaired non-parametric Mann–Whitney U -test. (C) Kinetics of doxorubicin
uptake by HL60-parental and HL60-100R cells. Cells were incubated with
5µM of doxorubicin at 37°C. After various time intervals, the cells were
washed in HBSS/5% FBS and analyzed in flow cytometry. (D) Quantification
of the flow cytometry data. Each data point represent the mean±SD of n=2
independent biological replicates. The data sets are significantly different
(*p-value=0.0320< 0.05). p-Value calculated by Wilcoxon matched-pairs
signed rank test. (E) In vitro confocal images of subcellular doxorubicin
fluorescence distribution in HL60-parental and HL60-100R cells and
respective quantification (F) for n=10 cells.
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FIGURE 4 | Sensitive cells accumulate more chemotherapeutical drug.
(A) In the presence of verapamil, the retention of CaAM is significantly
higher in the resistant cell lines, consistent with an expectable significant
reduction in the ABC transporters activity. (B) Cells were incubated with
5µM of doxorubicin and 10µM of verapamil at 37°C. Co-administration of
doxorubicin with verapamil is not sufficient to significantly increase the
uptake of doxorubicin in HL60-100R. (C) Doxorubicin uptake is similar
when the drug is administered alone or in combination with verapamil for
all cell lines. (D) Effect of PMA on HL-60 cells. Quantification of the flow
cytometry data of HL60-parental and HL60-100R cells incubated with
100 nM of PMA at 37°C for 15 min. Each data point represent the
mean±SD of n=3 independent biological replicates. The data sets are
significantly different (*p-value= 0.0279<0.05). p-value calculated by
two-way ANOVA.
importance, given that the reduced endocytosis might be directly
linked to the failure of MDR1 inhibitor drugs in clinical trials.
INSULIN DOES NOT STIMULATE ENDOCYTOSIS EQUALLY IN ALL
EXPERIMENTAL CONDITIONS
Finally, we also tested the effect of insulin on drug uptake
because stimulation of fluid-phase endocytosis by insulin is a
well-established phenomenon (9, 14, 15, 33, 39), which fuels an
on-going controversy in cancer therapy, as to whether or not
insulin potentiation therapy (IPT) has benefits in chemotherapy
outcome (6, 16, 40). Administration of insulin did not grossly
affect population growth and viability of HL60 cells, permitting
us to ask if co-administering PI and insulin would result in higher
uptake of PI in drug-resistant HL60 cells. Co-treatment of cells
with insulin and PI in regular growth medium, did not show any
effect on PI uptake in the resistant cell lines (Figure 5A) – as
opposed to treatment with PMA. However, when the cells were in
methylcellulose (used to hold cells under the microscope), insulin
administration resulted in an increase of PI accumulation in both
cell lines (Figures 5B; Figure S2 in Supplementary Material).
HL60-100R cells (purple) exhibited a more pronounced response
with a drastic accumulation of PI, reaching the plateau almost
immediately. HL60-parental cells (red) continued to uptake PI for
the entire duration of the experiment. Thus, insulin can promote
PI uptake but only when in methylcellulose culture raising the
baseline endocytosis in naive cells and more drastically, overcom-
ing the “adaptive” reduction of this process in the resistant HL60
cells. The reason for the distinct effect of insulin in liquid adherent
cell culture vs. suspension is still unknown.
DISCUSSION
Development of multi-drug resistance is a chief reason for failure
of chemotherapy. Here, we show that suppression of fluid-phase
endocytosis was directly linked to long-term drug resistance in
HL60 acute myeloid leukemic cells. This actively regulated cellu-
lar process might be associated with reduced clinical effectiveness
of cancer drugs. Our results are in line with previously reported
data showing defective uptake of cisplatin in resistant tumor
cells (27, 28).
We excluded the possibility that PI, used here to demonstrate
the contribution of uptake in the net accumulation of drugs in
the cell, is a substrate for MDR1, and corroborated its use as a
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FIGURE 5 | Insulin does not stimulate endocytosis equally in all experimental conditions. (A) In suspension culture conditions, PI endocytosis is
stimulated by PMA but not by insulin. (B) Quantification of fluid-phase endocytosis of PI accumulation in HL60-parentals (blue) and HL60-100R (green) and in
insulin co-treated HL60-parentals (red) and HL60-100R (purple). Each data point represent the mean±SD of n=10 individual cells.
marker for fluid-phase endocytosis. This report neither does sug-
gest that fluid-phase endocytosis is the sole or major mechanism
of drug resistance nor does it even exclude the contribution of
receptor-mediated endocytosis or differential cellular permeabil-
ity. Further exploration is needed to uncover the various mecha-
nisms of uptake and how they contribute to cellular homeostasis
(25, 37, 38). Comparison of changes in cellular permeability and
membrane transcytosis between parental and resistant cells would
still need to be investigated due to the non-specific nature of
evaluating fluid-phase endocytosis.
The study of endocytosis regulators, such as PIKfyve (33, 39)
and Dynamin-2 (6, 40), which have been previously explored,
will also help with future investigations. Recent reports suggest
that all cellular transport might be in some way carrier-mediated
and that passive diffusion is negligible (34, 41, 42). If true,
this would open a new line of research toward the identifica-
tion of the carriers involved in fluid-phase endocytosis or other
uptake processes as a pharmacological means to overcome resis-
tance, which has not been achieved using drugs that block ABC
transporters alone (35, 36, 43).
A previous study of cancer resistance has implicated reduced
endocytosis in multi-drug resistance (4, 44) but this present report
establishes a direct link between long-term cellular (non-genetic)
“adaptation” to drugs and fluid-phase endocytosis suggesting that
the reduced net uptake of drug might be just one step in the multi-
step, non-genetic phenotype change that sensitive cells undergo in
response to chemotherapy to cope with toxicity (21, 23) before
resistance becomes fixed through selection of adapted cells.
In summary, the present study demonstrates that a drug-uptake
mechanism, possibly fluid-phase endocytosis, is not active at the
same level in parental and resistant cells. The homeostatic regu-
lation assured by the endocytosis–exocytosis cycle is crucial for
normal cellular behavior, which might be the reason why disrup-
tion in this balance is often linked to disease (25, 45). The model of
MDR that is based on reduced drug accumulation owing to ABC
transporters alone cannot explain the present findings wherein
cancer cells suppress drug accumulation to below the baseline of
non-resistant cells. Here, we propose a revision to this model:
therapy-stressed cells, which actively induce MDR1 expression (9,
23) as an evolved response for the detoxification in adverse envi-
ronments, also induce, with some delay, a protective cell state in
which entry of toxins is blocked. A more detailed, mechanistic
study of the latter is needed to fully understand the role of cel-
lular endocytosis in health and disease and for the development
of new drugs that can counter the multifaceted biology of drug
resistance.
MATERIALS AND METHODS
CELL CULTURE
HL60 cells were cultured in Iscove’s Modified Dulbecco’s Medium
(IMDM, Invitrogen) supplemented with 20% fetal bovine serum
(FBS, Sigma), 1% l-glutamine, penicillin (100 U/mL, Invitro-
gen), and streptomycin (100 mg/mL, Invitrogen). Cell number
was monitored daily and culture was maintained at a density of
2× 105–2× 106 cells/mL. Cell number was monitored daily using
a BioRad automatic cell counter and viability was assessed by try-
pan blue exclusion (0.4% supplied with the cell counter slides and
added to the cells in a 1:1 v/v ratio according to manufacture’s
instructions). HL60-resistant cells were supplemented with the
respective concentration (10 or 100 nM) of vincristine (in H2O,
Sigma). The cells were passaged every 2–3 days and drug was added
freshly each time.
FLOW CYTOMETRY
Propidium iodide (Life Technologies) was added to suspension
cells in a concentration of 5µg/mL just before analysis unless
indicated otherwise. To measure fluid-phase uptake using fluo-
rescein isothiocyanate (FITC)-dextran, 1× 105 cells were washed
in Hank’s balanced salt solution (HBSS)/5% FBS and then incu-
bated with or without 1 mg/mL of FITC-dextran (Sigma, average
mol. wt. 70,000) in fresh medium at 37°C for 2 h. Doxorubicin
(Dox), verapamil (Ver), and PMA were all acquired from Sigma
in powder form and dissolved in DMSO (Sigma). Calcein AM
(CaAM, 1 mg/mL solution in anhydrous DMSO) was acquired
from Life Technologies. Flow cytometry analyses were performed
on a BD FACSCalibur cell cytometer and flow cytometry data were
analyzed using FlowJo software (Tree Star). When quantification
of data is presented, namely, mean values of the peak intensity,
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those were obtain by calculating the mean value of the distribution
using FlowJo.
MICROSCOPY AND DATA ANALYSIS
HL60 cells at a density of 1× 105 cells/mL were seeded for 30 min
in a 35 mm four-compartments glass bottom dishes (CELLview™,
Greiner Bio One). To each compartment we added 600µL of
fresh medium with methylcellulose (MethoCult™ H4100, Stem-
Cell Technologies) in a ratio 4:1. When adding PI, doxorubicin,
or insulin or any combination, the drugs were first added to fresh
medium and only then the mixture was added to methylcellulose.
As controls we used cells in dye-free medium. Cells were imaged
with a Zeiss LSM 510-Exciter (Fluar 20x/0.75 UV objective) using a
Pecon incubator XL (37°C, 5% CO2) and the images were analyzed
using LSM Aim Software. PI was excited with a 514 nm argon ion
laser and detected with a 560 nm long-pass filter. Doxorubicin was
excited with a 488 nm argon ion laser and detected with a 560 nm
long-pass filter. For quantification, we used CellTracker version 6.0
software [DTI Beacon Project, University of Manchester (5, 32)]
to mark cell boundaries of a single cell captured in consecutive
time course microscopy images. The program measured average
fluorescence intensity for total cell area and output that value,
along with the corresponding time, into a comma-separated values
(csv) file.
STATISTICAL ANALYSIS
The statistical tests were performed using GraphPad Prism ver-
sion 6.00 for MacOS, GraphPad Software, La Jolla, CA, USA,
www.graphpad.com.
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